ReviewInternational urology and nephrology2026
The mechanism of hypoxia-inducible factor-1α in gouty nephropathy.
Review in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Gouty nephropathy (GN) comprises a group of renal injuries caused by monosodium urate (MSU) deposition in the kidneys under conditions of long-term hyperuricemia (HUA), and its incidence has continued to rise each year. In the pathological process of GN, hypoxia-inducible factor-1α (HIF-1α) participates in the regulation of inflammation, oxidative stress, and renal interstitial fibrosis, showing dual influences on disease development. Therefore, the regulation of HIF-1α is considered one of the major strategies for GN treatment. Current therapeutic approaches involve direct suppression of its activity as well as indirect modulation. HIF stabilizers and related agents have displayed therapeutic potential for GN in animal experiments. Further clarification of the complicated mechanisms of HIF-1α during the pathological progression of GN may offer new ideas and potential targets for preventing and treating this disease.
Indexed as
Identifiers
42547749What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.